Nancy U. Lin, MD, discusses how she would use the HER2CLIMB regimen of tucatinib plus trastuzumab and capecitabine now that it has been approved for treatment of patients with HER2-positive metastatic breast cancer.
Nancy U. Lin, MD, associate professor of medicine at Harvard Medical School; associate chief of the Division of Breast Oncology at the Susan F. Smith Center for Women's Cancers; and director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute, discusses how she would use the HER2CLIMB regimen of tucatinib (Tukysa) plus trastuzumab (Herceptin) and capecitabine now that it has been approved for treatment of patients with HER2-positive metastatic breast cancer.
Patients had to be in their third line of treatment to be included in the HER2CLIMB trial, and that’s where Lin says she would use it in the clinic, instead of as a later-line regimen. She would move it up because of the potential benefits, including survival. The benefit with the triplet was seen in the overall population, not just patients with brain metastases.
This combination has a learning curve in terms of managing the toxicity profile, according to Lin. The adverse events were manageable in HER2CLIMB, and a lot of the toxicity came from what has been previously seen with capecitabine.
Most patients in this setting have already been exposed to trastuzumab by the time they enroll to the HER2CLIMB regimen. There can be some diarrhea and rash with tucatinib, but these events are less common than with other tyrosine kinase inhibitors, which target EGFR more strongly. Lin says there can be some increases in liver function blood tests that oncologists should monitor closely.
Overall, Lin thinks this regimen is manageable from a toxicity standpoint. The quality of life for patients while receiving this regimen can be good. There was a substudy in the HER2CLIMB trial, and those results will provide more information on how the triplet impacts patients.
<< View more resources and information for HER2-positive breast cancer
No Significant pCR Improvement With Neoadjuvant HP/Chemo Plus Atezolizumab in HER2+ Breast Cancer
December 8th 2023The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.
Read More
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2-Positive Early Breast Cancer
December 8th 2023After more than 8 years of follow-up, T-DM1 continued to improve invasive disease-free survival and overall survival in patients with HER2-positive early breast cancer that had residual invasive disease.
Read More
Trastuzumab Deruxtecan Shows Activity in Real-World mBC With Dynamic HER2
December 7th 2023The RELIEVE study looked at real-world patients receiving trastuzumab deruxtecan based on HER2 expression status and time to next treatment including in those whose HER2 status changed during course of treatment.
Read More
Tucatinib Plus T-DM1 Improves PFS in Previously Treated HER2+ Metastatic Breast Cancer
December 6th 2023The introduction of tucatinib to ado-trastuzumab emtansine significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer.
Read More